Selected data models

You must log in to select data models for download or further analysis.

25 Search results.
Relevance Rating New first Old first

NCT01013649 RTOG 0848 Phase III Pancreas-Resected + Adjuvant Treatment Systemic Treatment Summary Form (TF)

- 7/8/15 - 1 form, 7 itemgroups, 93 items, 1 language
Itemgroups: RTOG clinical trial administrative data, Summary of Systemic Treatment, Treatment Summary, Adverse Events, Laboratory Values, Lab results, Comments
NCT01013649 RTOG 0848 Phase III Pancreas-Resected + Adjuvant Treatment Systemic Treatment Summary Form (TF) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=689F0A8D-3BC3-3BA7-E040-BB89AD434E50

RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Surgery Form (S1) NCT01013649

- 6/21/15 - 1 form, 5 itemgroups, 57 items, 1 language
Itemgroups: Header module, Gastro intestinal Surgical Procedure, Other organs resected, Tumor invasion, Additional Pathologic Findings
RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Surgery Form (S1) NCT01013649 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=68B36F4B-6F1B-CD4B-E040-BB89AD4309CF

Pancreatic Cancer NCT01013649 Treatment - RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Additional Systemic Treatment Summary Form (AT) - 2891794v1.0 - RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Additional Systemic Treatment Summary Form (AT)

- 1/9/15 - 1 form, 6 itemgroups, 33 items, 1 language
Itemgroups: Header Module, Header, Summary of Systemic Treatment, Treatment Summary, Adverse Events, Footer Module
RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Additional Systemic Treatment Summary Form (AT) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6AFC2AE9-5C38-1FC0-E040-BB89AD4334D1

Pancreatic Cancer NCT01013649 Treatment - RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Systemic Treatment Summary Form (SF) - 2867004v1.0 - RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Systemic Treatment Summary Form (SF)

- 1/9/15 - 1 form, 6 itemgroups, 33 items, 1 language
Itemgroups: Header Module, Header, Summary of Systemic Treatment, Treatment Summary, Adverse Events, Footer Module
RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Systemic Treatment Summary Form (SF) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=690785CE-F693-0044-E040-BB89AD432A23

Pancreatic Cancer NCT01013649 Quality of Life - RTOG 0848 Phase III Pancreas-Resected + Adjuvant Treatment PROMIS Fatigue Short Form-1 Cover Sheet (PR) - 2865750v1.0 - RTOG 0848 Phase III Pancreas-Resected + Adjuvant Treatment PROMIS Fatigue Short Form-1 Cover Sheet (PR)

- 1/9/15 - 1 form, 4 itemgroups, 30 items, 1 language
Itemgroups: Header Module, Header, QOL Cover Sheet, PROMIS Fatigue Short Form 1
RTOG 0848 Phase III Pancreas-Resected + Adjuvant Treatment PROMIS Fatigue Short Form-1 Cover Sheet (PR) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=68B36F4B-6CF7-CD4B-E040-BB89AD4309CF

Pancreatic Cancer NCT01013649 Quality of Life - RTOG 0848 Phase III Pancreas-Resected + Adjuvant Treatment FACIT - Fatigue Cover Sheet (FA) - 2865273v1.0 - RTOG 0848 Phase III Pancreas-Resected + Adjuvant Treatment FACIT - Fatigue Cover Sheet (FA)

- 1/9/15 - 1 form, 4 itemgroups, 36 items, 1 language
Itemgroups: Header Module, Header, QOL Cover Sheet, FACIT-Fatigue Subscale
RTOG 0848 Phase III Pancreas-Resected + Adjuvant Treatment FACIT - Fatigue Cover Sheet (FA) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=68B33AD0-8068-FF39-E040-BB89AD430ECB

Pancreatic Cancer NCT01013649 On-Study - RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Post ARM 1 or 2 Tumor Status Form (F3) - 2865008v1.0 - RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Post ARM 1 or 2 Tumor Status Form (F3)

- 1/9/15 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Header Module, Header
RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Post ARM 1 or 2 Tumor Status Form (F3) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=68A15631-F4DE-4C22-E040-BB89AD431280

Pancreatic Cancer NCT01013649 Treatment - RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Radiotherapy Form (T1) - 2866961v1.0 - RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Radiotherapy Form (T1)

- 1/9/15 - 1 form, 1 itemgroup, 21 items, 1 language
Itemgroup: MODULE 1
RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Radiotherapy Form (T1) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=69073BF6-D406-B01F-E040-BB89AD4319AC

Pancreatic Cancer NCT00075686 Treatment - S0205 PAIN MEDICATION LOG - 2291766v3.0 - S0205 PAIN MEDICATION LOG

- 1/9/15 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Administrative documentation, Analgesics
S0205 PAIN MEDICATION LOG S0205 Gemcitabine With or Without Cetuximab as First-Line Therapy in Treating Patients With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E30D7C36-2312-0722-E034-0003BA12F5E7

Pancreatic Cancer NCT00075686 Treatment - SOUTHWEST ONCOLOGY GROUP S0205 TREATMENT SUMMARY FORM - 2307260v3.0 - SOUTHWEST ONCOLOGY GROUP S0205 TREATMENT SUMMARY FORM

- 1/9/15 - 1 form, 7 itemgroups, 30 items, 1 language
Itemgroups: Header, STATUS, TREATMENT, GEMCITABINE USE, CETUXIMAB USE: For Arm 1 patients only, Hospitalization, Comments
SOUTHWEST ONCOLOGY GROUP S0205 TREATMENT SUMMARY FORM S0205 Gemcitabine With or Without Cetuximab as First-Line Therapy in Treating Patients With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F2EB277F-E272-2226-E034-0003BA3F9857

The Effect of Albiglutide on Cardiac Repolarisation Compared with Placebo 107085 - Injection Site Reaction

- 11/19/18 - 1 form, 4 itemgroups, 25 items, 1 language
Itemgroups: Administrative data, Injection Site Reaction, Local reaction symptoms, Subjects with a severe injection site reaction or a severe systemic allergic reaction must have three 1mL serum samples obtained for immunogenicity testing.
Study ID: 107085 Clinical Study ID: GLP107085 Study Title: A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01406262 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2

The Effect of Albiglutide on Cardiac Repolarisation Compared with Placebo 107085 - Day 29: Study Drug Administration, Drug 2

- 11/15/18 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Administrative data, Study Drug Administration
Study ID: 107085 Clinical Study ID: GLP107085 Study Title: A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01406262 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial